BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11877760)

  • 1. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector.
    Rogers BE; Zinn KR; Lin CY; Chaudhuri TR; Buchsbaum DJ
    Cancer; 2002 Feb; 94(4 Suppl):1298-305. PubMed ID: 11877760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
    Rogers BE; McLean SF; Kirkman RL; Della Manna D; Bright SJ; Olsen CC; Myracle AD; Mayo MS; Curiel DT; Buchsbaum DJ
    Clin Cancer Res; 1999 Feb; 5(2):383-93. PubMed ID: 10037188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors.
    Nilsson O; Kölby L; Bernhardt P; Forssell-Aronsson E; Johanson V; Ahlman H
    Ann N Y Acad Sci; 2004 Apr; 1014():275-9. PubMed ID: 15153445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodality imaging of gene transfer with a receptor-based reporter gene.
    Chen R; Parry JJ; Akers WJ; Berezin MY; El Naqa IM; Achilefu S; Edwards WB; Rogers BE
    J Nucl Med; 2010 Sep; 51(9):1456-63. PubMed ID: 20720053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
    Celinski SA; Fisher WE; Amaya F; Wu YQ; Yao Q; Youker KA; Li M
    J Surg Res; 2003 Nov; 115(1):41-7. PubMed ID: 14572771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.
    Heidari P; Kunawudhi A; Martinez-Quintanilla J; Szretter A; Shah K; Mahmood U
    Theranostics; 2018; 8(12):3380-3391. PubMed ID: 29930736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor growth inhibition of paclitaxel-octreotide conjugates on human non small cell lung cancer: experiment with mice].
    Shen HC; Wang XW; Liu YG
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2498-503. PubMed ID: 19080633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re.
    Zinn KR; Buchsbaum DJ; Chaudhuri TR; Mountz JM; Grizzle WE; Rogers BE
    J Nucl Med; 2000 May; 41(5):887-95. PubMed ID: 10809205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
    Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
    Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
    Stolz B; Weckbecker G; Smith-Jones PM; Albert R; Raulf F; Bruns C
    Eur J Nucl Med; 1998 Jul; 25(7):668-74. PubMed ID: 9662587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
    Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
    Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.